Linnaeus Therapeutics
Linnaeus Therapeutics is a development-stage biotech company focused on identifying and developing small molecule agents for cancer treatment. Founded in 2016 as a Penn Center for Innovation UPstart company, it is based on discoveries from the Ridky lab at the University of Pennsylvania. The company develops therapies supported by clinical experience, targeting G protein-coupled estrogen receptor (GPER) among other receptors, with a mission to create safe and effective cancer therapeutics. Linnaeus has received multiple designations and funding, including orphan drug status, Fast Track designation, SBIR, and Series B financing, to advance its lead compound LNS8801 through clinical trials.
Industries
Nr. of Employees
small (1-50)
Patents
Enantiomerically purified GPER agonist for use in treating disease states and conditions
US-11760749-B2
View DetailsEnantiomerically purified GPER agonist for use in treating disease states and conditions
US-10934277-B2
View Details
Enantiomerically purified GPER agonist for use in treating disease states and conditions
US-11760749-B2
View DetailsEnantiomerically purified GPER agonist for use in treating disease states and conditions
US-10934277-B2
View DetailsProducts
Oral GPER agonist (lead clinical-stage small-molecule oncology therapeutic)
An orally bioavailable, highly specific small-molecule agonist of the G protein-coupled estrogen receptor (GPER) developed for treatment of multiple solid and hematologic cancers; demonstrated preclinical antitumor activity, target engagement, and combinatorial effects with immune checkpoint inhibitors.
Oral GPER agonist (lead clinical-stage small-molecule oncology therapeutic)
An orally bioavailable, highly specific small-molecule agonist of the G protein-coupled estrogen receptor (GPER) developed for treatment of multiple solid and hematologic cancers; demonstrated preclinical antitumor activity, target engagement, and combinatorial effects with immune checkpoint inhibitors.
Services
Design and conduct of multicenter early-stage oncology clinical trials including dose escalation, RP2D determination, and combination cohorts with immune checkpoint inhibitors.
Preclinical efficacy, pharmacology, biomarker studies, and toxicology to support IND-enabling development of small-molecule oncology candidates.
Preparation and management of regulatory interactions and filings with the U.S. FDA, pursuit of expedited development designations, and coordination of regulatory strategy for oncology programs.
Structuring and managing clinical collaboration agreements with larger pharmaceutical partners to evaluate combination regimens in defined patient populations.
Administration of federally funded research awards to support early-stage development activities.
Design and conduct of multicenter early-stage oncology clinical trials including dose escalation, RP2D determination, and combination cohorts with immune checkpoint inhibitors.
Preclinical efficacy, pharmacology, biomarker studies, and toxicology to support IND-enabling development of small-molecule oncology candidates.
Preparation and management of regulatory interactions and filings with the U.S. FDA, pursuit of expedited development designations, and coordination of regulatory strategy for oncology programs.
Structuring and managing clinical collaboration agreements with larger pharmaceutical partners to evaluate combination regimens in defined patient populations.
Administration of federally funded research awards to support early-stage development activities.
Expertise Areas
- Clinical trial management (early-stage oncology)
- Small-molecule oncology drug discovery
- GPCR-targeted therapeutics
- Preclinical pharmacology and in vivo efficacy
Key Technologies
- GPCR-targeted small-molecule agonists
- Oral small-molecule therapeutics
- In vivo murine cancer models
- Pharmacokinetics (PK) assessment
News & Updates
Linnaeus Therapeutics was granted orphan drug designation by the FDA for LNS8801 for treating metastatic cutaneous melanoma.
The U.S. Patent and Trademark Office issued a patent for LNS8801, supporting its development as a therapeutic agent.
Linnaeus announced the presentation of clinical data for LNS8801 at the 2022 ESMO Annual Meeting.
The company dosed the first patient in its phase 1/2 trial of LNS8801 for advanced cancer.
The first patient was dosed in a trial combining LNS8801 with pembrolizumab.
Linnaeus entered into a collaboration with Merck to evaluate LNS8801 with KEYTRUDA in advanced cancers.
Linnaeus Therapeutics was granted orphan drug designation by the FDA for LNS8801 for treating metastatic cutaneous melanoma.
The U.S. Patent and Trademark Office issued a patent for LNS8801, supporting its development as a therapeutic agent.
Linnaeus announced the presentation of clinical data for LNS8801 at the 2022 ESMO Annual Meeting.
The company dosed the first patient in its phase 1/2 trial of LNS8801 for advanced cancer.
The first patient was dosed in a trial combining LNS8801 with pembrolizumab.
Linnaeus entered into a collaboration with Merck to evaluate LNS8801 with KEYTRUDA in advanced cancers.